Validation of AML-Score in older adults receiving daunorubicin/cytarabine liposome intensive induction chemotherapy for treatment of secondary acute myeloid leukemia.

被引：0
|
作者：
Schmucker, Abigail
Leiby, Benjamin
Wilde, Lindsay
机构：
[1] Thomas Jefferson Univ, Sidney Kimmel Canc Ctr, Philadelphia, PA 19107 USA
[2] Thomas Jefferson Univ, Dept Pharmacol & Expt Therapeut, Philadelphia, PA 19107 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.e19000
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e19000
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Validation of AML-score in Older Adults Receiving CPX-351 Intensive Induction Chemotherapy for Treatment of Secondary Acute Myeloid Leukemia
    Schmucker, Abigail M.
    Leiby, Benjamin E.
    Wilde, Lindsay
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (03) : E206 - E212
  • [2] CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia
    Lancet, Jeffrey E.
    Uy, Geoffrey L.
    Cortes, Jorge E.
    Newell, Laura F.
    Lin, Tara L.
    Ritchie, Ellen K.
    Stuart, Robert K.
    Strickland, Stephen A.
    Hogge, Donna
    Solomon, Scott R.
    Stone, Richard M.
    Bixby, Dale L.
    Kolitz, Jonathan E.
    Schiller, Gary J.
    Wieduwilt, Matthew J.
    Ryan, Daniel H.
    Hoering, Antje
    Banerjee, Kamalika
    Chiarella, Michael
    Louie, Arthur C.
    Medeiros, Bruno C.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (26) : 2684 - +
  • [3] FDA Approval Summary: (Daunorubicin and Cytarabine) Liposome for Injection for the Treatment of Adults with High-Risk Acute Myeloid Leukemia
    Krauss, Aviva C.
    Gao, Xin
    Li, Liang
    Manning, Michael L.
    Patel, Paresma
    Fu, Wentao
    Janoria, Kumar G.
    Gieser, Gerlie
    Bateman, David A.
    Przepiorka, Donna
    Shen, Yuan Li
    Shord, Stacy S.
    Sheth, Christopher M.
    Banerjee, Anamitro
    Liu, Jiang
    Goldberg, Kirsten B.
    Farrell, Ann T.
    Blumenthal, Gideon M.
    Pazdur, Richard
    CLINICAL CANCER RESEARCH, 2019, 25 (09) : 2685 - 2690
  • [4] HIGH-DOSE CYTARABINE AND DAUNORUBICIN INDUCTION AND POSTREMISSION CHEMOTHERAPY FOR THE TREATMENT OF ACUTE MYELOGENOUS LEUKEMIA IN ADULTS
    PHILLIPS, GL
    REECE, DE
    SHEPHERD, JD
    BARNETT, MJ
    BROWN, RA
    FREILAHR, DA
    KLINGEMANN, HG
    BOLWELL, BJ
    SPINELLI, JJ
    HERZIG, RH
    HERZIG, GP
    BLOOD, 1991, 77 (07) : 1429 - 1435
  • [5] Validation of Kantarjian (2010) Model for Intensive Chemotherapy in Older Adults with Acute Myeloid Leukemia
    Tahata, Shawn
    Im, Annie
    Boyiadzis, Michael
    Normolle, Daniel
    BLOOD, 2018, 132
  • [6] Patterns of Undertreatment Among Patients with Acute Myeloid Leukemia (AML) Not Receiving Standard Intensive Induction Chemotherapy
    Hubscher, Elizabeth
    Sikirica, Slaven
    Bell, Timothy J.
    Brown, Andrew
    Welch, Verna L.
    Russell-Smith, Alexander
    D'Amico, Paul G.
    BLOOD, 2020, 136
  • [7] Seven-days administration of daunorubicin with cytarabine in the intensified induction therapy for adult acute myeloid leukemia.
    Usui, N
    Dobashi, N
    Asai, O
    Maki, N
    Yano, S
    Watanabe, H
    Uno, S
    Osawa, H
    Yahagi, Y
    Katori, M
    Nagamine, M
    Yamaguchi, H
    Saito, T
    Kasama, K
    Hirano, A
    Tajima, N
    Kuraishi, Y
    BLOOD, 1998, 92 (10) : 213B - 213B
  • [8] Quality of life and mood of older patients with acute myeloid leukemia (AML) receiving intensive and non-intensive chemotherapy
    El-Jawahri, Areej
    Abel, Gregory A.
    Traeger, Lara
    Waldman, Lauren
    Markovitz, Netana
    VanDusen, Harry
    Fathi, Amir
    Steensma, David P.
    LeBlanc, Thomas W.
    Horick, Nora K.
    DeAngelo, Daniel J.
    Wadleigh, Martha
    Hobbs, Gabriela
    Foster, Julia
    Brunner, Andrew M.
    Amrein, Philip
    Stone, Richard M.
    Temel, Jennifer S.
    Greer, Joseph A.
    LEUKEMIA, 2019, 33 (10) : 2393 - 2402
  • [9] Quality of life and mood of older patients with acute myeloid leukemia (AML) receiving intensive and non-intensive chemotherapy
    Areej El-Jawahri
    Gregory A. Abel
    Lara Traeger
    Lauren Waldman
    Netana Markovitz
    Harry VanDusen
    Amir Fathi
    David P. Steensma
    Thomas W. LeBlanc
    Nora K. Horick
    Daniel J. DeAngelo
    Martha Wadleigh
    Gabriela Hobbs
    Julia Foster
    Andrew M. Brunner
    Philip Amrein
    Richard M. Stone
    Jennifer S. Temel
    Joseph A. Greer
    Leukemia, 2019, 33 : 2393 - 2402
  • [10] Comparison of Liposomal Daunorubicin and Cytarabine Versus Cladribine and High-Dose Cytarabine-Based Induction Chemotherapy in Secondary Acute Myeloid Leukemia Patients (sAML) or Acute Myeloid Leukemia with Myelodysplastic Related Changes (AML-MRC)
    Denson, Ariel
    Caddell, Ryan J.
    Richter, Katherine A.
    Li, Jiannong
    Sweet, Kendra
    Kuykendall, Andrew T.
    Padron, Eric
    Komrokji, Rami S.
    Lancet, Jeffrey E.
    Talati, Chetasi
    Sallman, David A.
    BLOOD, 2021, 138
12345